Bullish penny-stock thesis on IMRN citing military/DoD backing, upcoming ProIBS launch, a 2026 Phase 2 trial, no dilution for a year, and a chart gap to fill.
IMRN — LONG The author argues IMRN has bottomed as a low-float biotech with huge backing from the military and Department of Defense and ongoing research relationships with major US military institutions. Catalysts cited are the imminent launch of ProIBS (originally scheduled for Q4) and initiation of a Phase 2 trial for IMM-200 in the first half of 2026, with no dilution and cash for the next year. The stock sits at $1.00 versus a 52-week high of $2.50, leaving a large daily-chart gap the author expects to be filled.
IMRN is a pharmacuetical play with huge backing by the military and department of defense. They have ongoing research relationships with major US military institutions They are planning to launch ProIBS any day now (originally scheduled for Q4) + are initiating a phase 2 clinical trial for IMM-200 during the first half of 2026..
This Reddit post, published January 12, 2026, features u/blakeley314 discussing IMRN. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/blakeley314 · Tickers: IMRN